Centene Raises 2026 Guide, But Part D Risk and Board Shakeup Weigh
CNC has more than doubled off its 52-week low of $25.075 on elevated volume (2.1× avg).
Summary
Centene raised its full-year 2026 revenue guide to $193.5–$197.5B and adjusted EPS floor above $4.80 after a strong Q2 (GAAP EPS $2.19 vs. -$0.51 last year). However, two new developments overshadow the beat: the retirement of board member Kenneth A. Burdick and appointment of Paul J. Diaz, and a report that the U.S. will end Medicare Part D subsidies in 2027, directly hitting Centene's WellCare PDP business. Shares fell ~3% after-hours on the Part D news. The Part D exposure introduces a significant regulatory overhang that could pressure future earnings, while the board change adds governance uncertainty. This follows a series of positive Q2 reports and a recent Illinois Medicaid contract win, but the Part D risk is a fresh, material negative that traders need to price in immediately.
At the time of this announcement, CNC was trading at $62.51 on NYSE in the Life Sciences sector, with a market capitalization of approximately $31.6B. The 52-week trading range was $25.08 to $69.36. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.